Literature DB >> 36207638

New and effective EGFR-targeted fluorescence imaging technology for intraoperative rapid determination of lung cancer in freshly isolated tissue.

Changjian Li1,2, Jiahui Mi3, Yueqi Wang4, Zeyu Zhang1,2, Xiaoyong Guo4,5, Jian Zhou6, Zhenhua Hu7, Jie Tian8,9,10,11.   

Abstract

PURPOSE: During lung cancer surgery, it is very important to define tumor boundaries and determine the surgical margin distance. In previous research, systemically application of fluorescent probes can help medical professionals determine the boundaries of tumors and find small tumors and metastases, thereby improving the accuracy of surgical resection. However, there are very few safe and effective probes that can be applied to clinical trials up to now, which limits the clinical application of fluorescence imaging. Here we developed a new technology that can quickly identify the tumor area in the resected lung tissue during the operation and distinguish the tumor boundary and metastatic lymph nodes. EXPERIMENTAL
DESIGN: For animal studies, a PDX model of lung cancer was established. The tumors, lungs, and peritumoral muscle tissues of tumor-bearing mice were surgically removed and incubated with a probe targeting epidermal growth factor receptor (EGFR) for 20 min, and then imaged by a closed-field near-infrared two-zone (NIR-II) fluorescence imaging system. For clinical samples, ten surgically removed lung tissues and 60 lymph nodes from 10 lung cancer patients undergoing radical resection were incubated with the targeting probe immediately after intraoperative resection and imaged to identify the tumor area and distinguish the tumor boundary and metastatic lymph nodes. The accuracy of fluorescence imaging was confirmed by HE staining and immunohistochemistry.
RESULTS: The ex vivo animal imaging experiments showed a fluorescence enhancement of tumor tissue. For clinical samples, our results showed that this new technology yielded more than 85.7% sensitivity and 100% specificity in identifying the tumor area in the resected lung tissue. The average fluorescence tumor-to-background ratio was 2.5 ± 1.3. Furthermore, we also used this technique to image metastatic lymph nodes intraoperatively and showed that metastatic lymph nodes have brighter fluorescence than normal lymph nodes, as the average fluorescence tumor-to-background signal ratio was 2.7 ± 1.1. Calculations on the results of the fluorescence signal in relation to the number of metastatic lymph nodes yielded values of 77.8% for sensitivity and 92.1% for specificity. We expect this new technology to be a useful diagnostic tool for rapid intraoperative pathological detection and margin determination.
CONCLUSIONS: By using fluorescently labeled anti-human EGFR recombinant antibody scFv fragment to incubate freshly isolated tissues during surgery, the probes can quickly accumulate in lung cancer tissues, which can be used to quickly identify tumor areas in the resected lung tissues and distinguish tumor boundaries and find metastases in lymph nodes. This technology is expected to be used for rapid intraoperative pathological detection and margin determination.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Epidermal growth factor receptor; Fluorescence-labeled antibody probe; Intraoperative imaging technology; Lung cancer; Surgical tumor resection

Year:  2022        PMID: 36207638     DOI: 10.1007/s00259-022-05975-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  28 in total

1.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

2.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 3.  Latest developments in molecular tracers for fluorescence image-guided cancer surgery.

Authors:  Sophie Hernot; Labrinus van Manen; Pieterjan Debie; Jan Sven David Mieog; Alexander Lucas Vahrmeijer
Journal:  Lancet Oncol       Date:  2019-07       Impact factor: 41.316

4.  Cancer statistics, 2022.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2022-01-12       Impact factor: 508.702

5.  Targeted Intraoperative Molecular Imaging for Localizing Nonpalpable Tumors and Quantifying Resection Margin Distances.

Authors:  Gregory T Kennedy; Feredun S Azari; Elizabeth Bernstein; Isvita Marfatia; Azra Din; John C Kucharczuk; Philip S Low; Sunil Singhal
Journal:  JAMA Surg       Date:  2021-11-01       Impact factor: 16.681

Review 6.  Intraoperative pathology consultation during urological surgery: Impact on final margin status and pitfalls of frozen section diagnosis.

Authors:  Hiroshi Miyamoto
Journal:  Pathol Int       Date:  2021-06-21       Impact factor: 2.534

Review 7.  Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology.

Authors:  Chongwei Chi; Yang Du; Jinzuo Ye; Deqiang Kou; Jingdan Qiu; Jiandong Wang; Jie Tian; Xiaoyuan Chen
Journal:  Theranostics       Date:  2014-08-15       Impact factor: 11.556

8.  Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers.

Authors:  Susanne Kossatz; Giacomo Pirovano; Paula Demétrio De Souza França; Arianna L Strome; Sumsum P Sunny; Daniella Karassawa Zanoni; Audrey Mauguen; Brandon Carney; Christian Brand; Veer Shah; Ravindra D Ramanajinappa; Naveen Hedne; Praveen Birur; Smita Sihag; Ronald A Ghossein; Mithat Gönen; Marshall Strome; Amritha Suresh; Daniela Molena; Ian Ganly; Moni A Kuriakose; Snehal G Patel; Thomas Reiner
Journal:  Nat Biomed Eng       Date:  2020-03-12       Impact factor: 25.671

9.  Feasibility of intraoperative diagnosis of lung adenocarcinoma in situ to avoid excessive resection.

Authors:  Toshiyuki Shima; Tomonari Kinoshita; Naomichi Sasaki; Mao Uematsu; Yusuke Sugita; Reiko Shimizu; Masahiko Harada; Tsunekazu Hishima; Aya Yamamoto; Hirotoshi Horio
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

10.  Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.

Authors:  Zhouguang Hui; Yu Men; Chen Hu; Jingjing Kang; Xin Sun; Nan Bi; Zongmei Zhou; Jun Liang; Jima Lv; Qinfu Feng; Zefen Xiao; Dongfu Chen; Yan Wang; Junling Li; Jie Wang; Shugeng Gao; Luhua Wang; Jie He
Journal:  JAMA Oncol       Date:  2021-08-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.